Wegovy Significantly Reduces Severe Obesity in Children Aged 6 and Older
A global Phase 3 trial reveals that the weight-loss injection Wegovy significantly reduces BMI and obesity severity in children aged 6 to 11 when combined with lifestyle changes.

A groundbreaking international Phase 3 trial reveals that the once-weekly weight-loss injection Wegovy (semaglutide) significantly reduces body mass index (BMI) in children aged 6 to 11 suffering from severe obesity. The findings were published in The New England Journal of Medicine and presented simultaneously at the ObesityWeek 2026 international conference in Washington.
Clinical Trial Design and Methodology
The study, designated STEP Young, enrolled 167 children with obesity, of whom over 85% suffered from severe grade 2 or grade 3 obesity. The cohort included 16 participants from Israel across three participating medical centers: Schneider Children's Medical Center, Shamir Medical Center (Assaf Harofeh), and Rambam Health Care Campus. The double-blind trial randomized participants into two groups: 112 children received weekly semaglutide injections, while 55 children received a placebo. Both groups received concurrent lifestyle modification guidance, including calorie-reduced diets and increased physical activity. Maximum semaglutide dosages were tailored to baseline body weight, ranging from 1.7 to 2.4 milligrams weekly.
Significant BMI Reductions and Findings
At the end of 68 weeks, the semaglutide group demonstrated an average estimated BMI reduction of 13.5%, compared to a 2.7% increase in the placebo group, marking a statistically significant net difference of 16.2 percentage points. In an efficacy analysis assuming treatment adherence, nearly 80% of children receiving the drug achieved at least a 10% reduction in BMI, compared to zero children in the placebo group. Furthermore, approximately 40% of the children treated with semaglutide no longer met the clinical definition of obesity by week 68.
Specialists emphasize that in pediatric populations, BMI is evaluated relative to age and sex due to natural growth processes, meaning percentage drops in BMI do not directly equate to identical percentage drops in total body weight. Follow-up evaluations at 104 weeks—roughly two years from the study's commencement—showed a sustained average BMI reduction of 9.4% in the semaglutide adherence cohort, contrasted with an 8.4% increase among placebo recipients.
Medical Perspectives and Cardiometabolic Impact
Professor Zohar Landau, head of pediatric endocrinology and diabetes at Meuhedet Health Services, highlighted the profound implications of these results for young patients and their families.
"Severe childhood obesity is not merely a matter of weight, but a chronic disease that profoundly impacts a child's physical health, emotional well-being, and daily functioning."
Beyond weight loss, researchers observed improvements in several cardiometabolic markers linked to cardiovascular health and metabolism. Early-onset childhood obesity carries heightened risks for type 2 diabetes, hypertension, dyslipidemia, and obstructive sleep apnea. Medical experts note that pharmacotherapy combined with lifestyle changes can fundamentally alter a child's long-term health trajectory.
Safety Profile and Regulatory Status
The safety and tolerability profile of semaglutide observed in the trial mirrored findings from prior adult and pediatric studies, with no unexpected safety signals or adverse effects on growth or sexual development. Common side effects primarily involved the gastrointestinal tract, including nausea, vomiting, diarrhea, constipation, and abdominal pain, alongside headaches, fatigue, and dizziness.
In the USA, the medication carries a prominent safety warning regarding potential risks of thyroid C-cell tumors, including medullary thyroid carcinoma, contraindicating its use in patients with a personal or familial history of specific endocrine conditions. Currently, Wegovy is not approved in the USA for pediatric obesity in children under 12, though last year it was added to Israel's national list of health services for adolescents aged 12 to 18 under specific medical criteria. Researchers emphasize that further regulatory review and long-term monitoring are required before clinical guidelines can be formally expanded to younger children.



